Vuse vape

Vuse is the world's largest e-cigarette brand, with annual sales reaching several billion pounds. However, its development history is more like a prism, reflecting the current predicament of the global e-cigarette industry: between the industry narrative of "reducing harm" and the actual public health risks, and between the huge commercial interests and the increasingly strict legal regulations, there are repeated conflicts and negotiations.
?? Vuse Overview
Aspect Details
Parent Company British American Tobacco (BAT), acquired Reynolds American in 2017 and became the sole owner.
Brand Positioning BAT's core e-cigarette brand, aiming to provide "harm-reducing alternatives" for adult smokers.
Market Position Top e-cigarette brand by global value; ranks second in the US market (accounting for approximately 34%-40% of sales, second only to JUUL).
Target Users Adult smokers and e-cigarette users.
?? Core Product Line
The main products of Vuse all adopt a closed cartridge system, with the following core specifications:
Product Series Target Audience Nicotine Concentration (Eliquid) Eliquid Capacity
Vuse Alto Mainstream refillable device, market leader, contributing nearly 90% of Vuse's revenue in the US Common 1.8%, 2.4%, 5% 2 mL
Vuse Solo Early classic model, resembling traditional cigarettes in shape Common 14mg, 29mg, 36mg, and 4.8% -
Vuse Vibe Early model, relatively niche 3.0% 2 mL
Vuse Ciro Early model, relatively niche - -
Vuse ePod Targeting international markets such as Europe Common 20 mg/mL (in line with EU standards) 1.9 mL
Vuse Go Disposable e-cigarette, focusing on European markets such as the UK and Germany - -
Vuse Ultra Newly launched high-end product with an intelligent screen in 2025 - -
Vuse One Disposable e-cigarette, using synthetic nicotine, aiming to bypass FDA approval - -
?? Market Status and Challenges
Vuse's global market value share exceeded 25% in 2024, but has faced growth bottlenecks in the past two years:
Sales decline: In the first half of 2025, sales dropped by 12.9% compared to the previous year. For the entire year (the fiscal year 2025), the sales of vaping electronic cigarettes decreased by 13% year-on-year.
Revenue under pressure: In the first half of 2025, revenue decreased by 15% compared to the previous year. Although it returned to growth in the US market in the second half of the year, the overall revenue was still affected. Uncertainties in US regulations and the proliferation of illegal disposable products were the main reasons.
⚖️ FDA Regulatory Storm: A Long Battle
The history of Vuse is almost a history of its battles with the FDA. The core outcome is: tobacco flavors were approved, while menthol and other flavorings were banned. Some products are still being sold illegally.
Why was flavoring banned? The FDA's stance is clear: because flavored e-cigarettes are overly attractive to teenagers, posing a "known and significant risk", and manufacturers have failed to provide sufficient evidence to prove that their products offer additional benefits to adult smokers that outweigh this risk.
Key timeline of the Vuse vs. FDA ruling:
Date Event FDA Decision Product Type Current Status
October 2021 Vuse Solo Authorization Marketing Order (MGO) Tobacco flavor ✅ Available for sale
March 2022 Vuse Solo Marketing Rejection Order (MDO) (later partially withdrawn) Mint flavor ❌ Banned
May 2022 Vuse Ciro, Vuse Vibe Authorization Marketing Order (MGO) Only original flavor (tobacco) ✅ Available for sale
July 2024 Vuse Alto Authorization Marketing Order (MGO) Tobacco flavor ✅ Available for sale
March 2024 First Marketing Rejection Order (MDO) for Vuse Alto Mint flavor ❌ Administrative suspension, challenge in progress
March 2026 Vuse Solo Marketing Rejection Order (MDO) Two mint flavors (4.8% concentration) ❌ Banned
May 2026 Vuse Alto Marketing Rejection Order (MDO) Six flavors (including mint) ❌ Banned
Continuous Vuse One Has never been authorized, illegal sales Disposable electronic cigarette ⚠️ Illegal (FDA warning)
Severe criticism from the public health perspective: There is significant controversy regarding the basis of FDA's own decisions. Authoritative academic criticism points out that when the FDA approved Vuse Solo, it failed to fully assess the product's appeal to teenagers and was unable to prove that it has clear smoking cessation benefits for adult smokers, equivalent to gambling on a unproven "health benefit" with the huge risk of teenage addiction.
?? Health Risks: What Science Says
The official stance is clear: "All tobacco products are harmful and addictive. Non-smokers, especially young people, should not start using them."
The positive arguments for Vuse: Some experts in the scientific community believe that Vuse and other electronic cigarettes can serve as alternatives to reduce risks. The Vuse website claims that its products contain 99% less harmful substances than cigarettes; in vitro toxicological studies show that its indicators such as cytotoxicity and genotoxicity are lower than those of traditional cigarettes. Some research indicates that approximately 45% of Alto users have completely quit traditional cigarettes.
Opposition voices and undeniable evidence:
Potential serious health hazards: E-cigarettes can exacerbate respiratory problems, increase the risk of COVID-19 infection, and be associated with acute lung injury. Although EVALI is mainly related to illegal THC products, there are still case reports of non-THC users.
Clear physiological effects: Research has confirmed that after using Vuse products, the heart rate, systolic blood pressure, and diastolic blood pressure of users all increase.
"Reducing harm" is not "harmless": This is a key phrase used by Vuse in their marketing, but it is by no means a "healthy product" when compared to traditional cigarettes which contain 69 known carcinogens.
Teenage addiction risk: Vuse is the second most commonly used e-cigarette brand among American high school students, with approximately 10% of teenage users choosing it.

?? Summary
Vuse is not merely a consumer product. It represents the transformation of traditional tobacco giants, the contest of public health policies, and the health controversies of emerging technologies. Judging from the claims of harm reduction, its safety is far from being impeccable; from the perspective of business, its global leadership position is facing significant challenges; and from the perspective of legal regulation, every step it takes is fraught with difficulties.